Please Wait
Applying Filters...
menu
    • menu
    Gangwal Healthcare is powered by innovation, driving health, wellness & healing.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Synnat Pharma is one of the leading active pharmaceutical ingredients and intermediates manufacturers.

    Virtual Booth

    Contact Supplier

    Rusan Pharma: Over 30 years of specializing in the treatment of Addiction and Pain Management.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Fasedienol

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    $ API Ref.Price (USD/KG) : 14,120Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: 23062-06-8, Fasedienol, Aloradine, 4,16-androstadien-3-beta-ol, 4,16-androstadien-3beta-ol, Dtw1nj7ijh
    Molecular Formula
    C19H28O
    Molecular Weight
    272.4  g/mol
    InChI Key
    NYVFCEPOUVGTNP-DYKIIFRCSA-N
    FDA UNII
    DTW1NJ7IJH
    PH94B is being developed by Pherin Pharmaceuticals, Inc. for the treatment of social phobias (generalized anxiety disorder). It is a member of a new family of pharmaceutical compounds called vomeropherins.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    (3S,8S,9S,10R,13R,14S)-10,13-dimethyl-2,3,6,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-ol
    2.1.2 InChI
    InChI=1S/C19H28O/c1-18-9-3-4-16(18)15-6-5-13-12-14(20)7-11-19(13,2)17(15)8-10-18/h3,9,12,14-17,20H,4-8,10-11H2,1-2H3/t14-,15-,16-,17-,18-,19-/m0/s1
    2.1.3 InChI Key
    NYVFCEPOUVGTNP-DYKIIFRCSA-N
    2.1.4 Canonical SMILES
    CC12CCC3C(C1CC=C2)CCC4=CC(CCC34C)O
    2.1.5 Isomeric SMILES
    C[C@]12CC[C@H]3[C@H]([C@@H]1CC=C2)CCC4=C[C@H](CC[C@]34C)O
    2.2 Other Identifiers
    2.2.1 UNII
    DTW1NJ7IJH
    2.3 Synonyms
    2.3.1 Depositor-Supplied Synonyms

    1. 23062-06-8

    2. Fasedienol

    3. Aloradine

    4. 4,16-androstadien-3-beta-ol

    5. 4,16-androstadien-3beta-ol

    6. Dtw1nj7ijh

    7. (3s,8s,9s,10r,13r,14s)-10,13-dimethyl-2,3,6,7,8,9,10,11,12,13,14,15-dodecahydro-1h-cyclopenta[a]phenanthren-3-ol

    8. Androsta-4,16-dien-3-ol, (3b)-

    9. (3s,8s,9s,10r,13r,14s)-10,13-dimethyl-2,3,6,7,8,9,11,12,14,15-decahydro-1h-cyclopenta[a]phenanthren-3-ol

    10. (3as,3bs,7s,9ar,9bs,11ar)-9a,11a-dimethyl-3h,3ah,3bh,4h,5h,7h,8h,9h,9ah,9bh,10h,11h,11ah-cyclopenta[a]phenanthren-7-ol

    11. 4-androstadienol

    12. Unii-dtw1nj7ijh

    13. Fasedienol [inn]

    14. Aloradine [who-dd]

    15. Ph94b

    16. Androsta-4,16-dien-3beta-ol

    17. Schembl4075431

    18. Androsta-4,16-diene-3beta-ol

    19. Dtxsid901032322

    20. (3b)-androsta-4,16-dien-3-ol

    21. Yaa06206

    22. Mfcd00271236

    23. Zinc34031047

    24. Akos028109412

    25. As-60043

    26. Androsta-4,16-dien-3-ol, (3.beta.)-

    27. Hy-145567

    28. Cs-0376082

    29. Q20707597

    2.4 Create Date
    2006-10-25
    3 Chemical and Physical Properties
    Molecular Weight 272.4 g/mol
    Molecular Formula C19H28O
    XLogP34.6
    Hydrogen Bond Donor Count1
    Hydrogen Bond Acceptor Count1
    Rotatable Bond Count0
    Exact Mass272.214015512 g/mol
    Monoisotopic Mass272.214015512 g/mol
    Topological Polar Surface Area20.2 Ų
    Heavy Atom Count20
    Formal Charge0
    Complexity476
    Isotope Atom Count0
    Defined Atom Stereocenter Count6
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Indication

    Intended for the acute treatment of social phobia.

    5 Pharmacology and Biochemistry
    5.1 Pharmacology

    Vomeropherin compounds are directly delivered to the nasal passages using either a metered nasal spray or a metered nasal aerosol. By virtue of the chemoreceptors location in the nasal passages, direct connections to the hypothalamus and limbic system and the ability of our compounds to act locally, vomeropherins do not need to achieve systemic absorption and distribution. This provides a significant therapeutic advantage over traditional therapeutics targeted at the hypothalamus and limbic system that require access to systemic circulation and must cross the blood-brain barrier followed by uptake into the brain to exert effects.

    5.2 Absorption, Distribution and Excretion

    Absorption

    Absorbed following nasal administration.

    5.3 Mechanism of Action

    There is little information available on the mechanism of action of vomeropherins. These compounds are delivered to the nasal passages and bind to chemoreceptors that in turn affect the hypothalamus and the limbic system.